V Square Quantitative Management LLC Purchases 738 Shares of IQVIA Holdings Inc. (NYSE:IQV)

V Square Quantitative Management LLC lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 80.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,658 shares of the medical research company’s stock after acquiring an additional 738 shares during the quarter. V Square Quantitative Management LLC’s holdings in IQVIA were worth $419,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in IQV. Lazard Asset Management LLC lifted its stake in shares of IQVIA by 2.9% during the 3rd quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company’s stock worth $568,460,000 after acquiring an additional 80,189 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of IQVIA by 4.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock worth $532,070,000 after purchasing an additional 93,194 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in IQVIA by 3.4% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,325,198 shares of the medical research company’s stock valued at $457,483,000 after buying an additional 77,422 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in IQVIA by 339.6% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after acquiring an additional 1,597,003 shares in the last quarter. Finally, Capital Research Global Investors increased its position in shares of IQVIA by 42.2% during the fourth quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after acquiring an additional 592,372 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Kevin C. Knightly sold 8,607 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the transaction, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on IQV. BTIG Research assumed coverage on IQVIA in a research report on Tuesday, February 13th. They set a “buy” rating and a $285.00 target price for the company. Barclays raised their target price on shares of IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Guggenheim lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Evercore ISI lowered their target price on IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a report on Friday, May 3rd. Finally, Robert W. Baird decreased their price objective on IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a research note on Friday, May 3rd. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $257.57.

IQVIA Stock Performance

IQVIA stock traded down $3.38 during trading hours on Wednesday, hitting $226.00. 1,155,690 shares of the stock traded hands, compared to its average volume of 959,234. The firm’s 50 day moving average price is $238.14 and its 200-day moving average price is $228.32. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88. The stock has a market capitalization of $41.18 billion, a price-to-earnings ratio of 30.87, a P/E/G ratio of 2.31 and a beta of 1.52. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.